Close Close
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
ThinkAdvisor
A Wall Street street sign

Life Health > Life Insurance

Mortality Is Still Running High, Globe Life Tells Wall Street

X
Your article was successfully shared with the contacts you provided.

What You Need to Know

  • Ameriprise variable annuity sales increased to $1.1 billion, from $923 million.
  • Globe Life reported higher net income on higher revenue.
  • Globe Life executives implied that excess mortality may now amount to less than 1% of death claims.

Executives at Ameriprise Financial and Globe Life are happy with their companies’ life insurance and annuity operations — and the U.S. death rate is still a bit higher than it was before early 2020, when the COVID-19 pandemic showed up.

The companies started life and annuity issuers’ third-quarter earnings release season Wednesday, and the executives briefed securities analysts on the results Thursday, during conference calls that were streamed live and online.

Ameriprise Chief Executive Officer Jim Cracchiolo said demand for the company’s registered index-linked annuities and variable annuities without living benefits guarantees was strong. “Sales were up 18% from a year ago,” he said.

Tom Kalmbach, the chief financial officer of Globe Life, touched on the matter of life insurance claims. “We’re continuing to see excess mortality even in the third quarter,” he said. “It is better than what we assumed. But we still expect to see some excess mortality in 2024.”

What it means: Life and annuity issuers are doing well, and the lingering effects of COVID-19 are not big enough to have much effect on the companies’ earnings, but the increased mortality is adding a somber note to the earnings calls.

Ameriprise: Ameriprise, a diversified financial services company, reported $872 million in net income for the third quarter on $3.9 billion revenue in revenue, compared with $1.1 billion in net income on $3.5 billion in revenue for the third quarter of 2022.

At the Minneapolis-based company’s advice and wealth management unit, adjusted operating total net revenues increased to $2.4 billion, from $2.2 billion.

Distribution fees fell to $559 million, from $579 million, but advisory fees increased to $1.2 billion, from $1.1 billion, and financial planning fees increased to $102 million, from $97 million.

At the Retirement & Protection Solutions business, which sales the life insurance and annuities, adjusted operating total net revenues rose to $876 million, from $783 million, thanks in part to a boost from higher interest rates. The unit’s net investment income climbed 42%, to $215 million.

Variable annuity deposits rose to $1.1 billion, from $923 million, and life insurance policyholder reserves increased to $15 billion, from $14 billion.

Life insurance coverage in force held steady at about $198 billion, and net amount at risk per life fell 4%, to $37,917.

Globe Life: Globe Life, a McKinney, Texas-based insurer that focuses mainly on the life and health markets, with some annuity sales, reported $257 million in net income for the third quarter on $1.4 billion in revenue, up from $191 million in net income on $1.3 billion in revenue for the year-earlier quarter.

Both life and health premium revenue were up, and net investment income increased to $267 million, from $247 million.

Mortality: During the Globe Life earnings call, Kalmbach, the CFO, and Frank Svoboda, the CEO, took several questions about mortality from the securities analysts, who seemed to be a little surprised to hear that mortality is still higher than it used to be.

Svoboda noted that the fluctuations might amount to just $2 million to $3 million, and that Globe Life typically pays about $300 million to $400 million in life insurance claims per quarter.

“That’s not a really high level of difference,” he said.

But he and Kalmbach noted that mortality is up partly because of COVID-19 itself and partly because of elevated death rates for conditions such as cancer.

The executives emphasized that Globe Life has assumed that mortality would be continue to be higher than it was before the pandemic, and that current mortality levels are within the projected range.

“It’s just going to take some time to go back to more normal mortality levels,” Kalmbach said.

He said the company expects mortality to be lower in 2024 but still higher than the pre-pandemic normal.

Credit: Adobe Stock


NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.